|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||26.80 - 26.80|
|52-week range||25.81 - 32.10|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||19.33|
|Forward dividend & yield||0.44 (1.65%)|
|Ex-dividend date||10 May 2021|
|1y target est||N/A|
ST. GALLEN, Switzerland & SAN DIEGO, Calif., September 16, 2021--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005966/en/
ST. GALLEN, Switzerland, August 31, 2021--Regulatory News: Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of their key products, Ferinject® and Veltassa®.
Cara Therapeutics (NASDAQ: CARA) was a hot stock on Tuesday. One of the formerly clinical-stage biotech's drug candidates won FDA approval, and investors reacted in the usual manner. The biotech company's most promising drug, Korsuva --- developed with Switzerland-based Vifor Pharma -- addresses this medical challenge sufficiently to win that all-important FDA approval.